|
Medullary carcinoma of thyroid
|
|
0.710 |
GeneticVariation
|
BEFREE |
Of the seven RET wild-type MTCs, four cases (57.1 %) harbored a RAS mutation: three in HRAS (all Q61R) and one in KRAS (G12R).
|
24828033 |
2014 |
|
Medullary carcinoma of thyroid
|
|
0.710 |
GeneticVariation
|
CLINVAR |
|
|
|
|
Colorectal Carcinoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Review of colorectal carcinomas with known KRAS and NRAS genotype revealed that none of 62 wild-type tumors or 47 mutants other than Q61R were SP174 positive.
|
28353383 |
2017 |
|
Colorectal Carcinoma
|
|
0.710 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Multiple Myeloma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
|
|
|
|
Colorectal Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Other mutations included: 1/78 (1.3%) successfully amplified tumor samples with TERT<sup> C228T</sup>; 2/79 (2.5%) NRAS 61 (c.181C>A and c.182A>G); 1/73 (1.4%) PIK3CA exon 9 (c.1589A>G and c.1598C>T in one tumor); 1/79 (1.3%) PIK3CA exon 20 (c.2951G>A); and 1/74 (1.4%) PTEN exon 5 (c.295G>A).
|
27824297 |
2017 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Next-generation sequencing identified recurrent mutations in HRAS (Q61R) in 3 of 5 IUPs, described for the first time in this neoplasm.
|
25097040 |
2014 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Review of colorectal carcinomas with known KRAS and NRAS genotype revealed that none of 62 wild-type tumors or 47 mutants other than Q</span>61R were SP174 positive.
|
28353383 |
2017 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
melanoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The rarity of HRAS and KRAS Q61R mutants in malignant melanoma</span> let previous investigations erroneously conclude that SP174 is specific for NRAS Q61R-mutant protein.
|
29206715 |
2018 |
|
melanoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Mutations in RAS genes (HRAS G13R, KRAS G12D, KRAS Q61R, NRAS Q61R) were detected in benign lesions and HRAS Q61R, NRAS Q61K mutations in PTCs.
|
31085772 |
2019 |
|
Carcinoma of lung
|
|
0.020 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
Carcinoma of lung
|
|
0.020 |
GeneticVariation
|
BEFREE |
To begin with, we developed a pipeline to utilize a set of computational tools in order to obtain the most deleterious nsSNPs (Q22K, Q61P, and Q61R) associated with lung cancer in the human KRAS gene.
|
31117243 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The BRAF T1799A mutation was detected in 10 PTC cases, while two different NRAS mutations in codon 61 (C181A and A182G) were found in 2 PTC cases.
|
30361901 |
2018 |
|
Chronic Lymphocytic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.
|
9139869 |
1997 |
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
To begin with, we developed a pipeline to utilize a set of computational tools in order to obtain the most deleterious nsSNPs (Q22K, Q61P, and Q61R) associated with lung cancer in the human KRAS gene.
|
31117243 |
2019 |
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
This system allowed us to rapidly compare the ability of 12 different KRAS mutations (G12A, G12C, G12D, G12F, G12R, G12S, G12V, G13C, G13D, Q61L, Q61R and A146T) to drive pancreatic tumorigenesis in vivo.
|
25065594 |
2015 |
|
Adult Diffuse Large B-Cell Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.
|
9139869 |
1997 |
|
Trichilemmoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The high frequency of HRAS activating mutations, including the c.182A>G substitution, which was rather rare in NS, suggests that most trichilemmomas are authentic neoplasms.
|
24890286 |
2014 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
|
0.010 |
GeneticVariation
|
BEFREE |
Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.
|
9139869 |
1997 |
|
Inverted urothelial papilloma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Next-generation sequencing identified recurrent mutations in HRAS (Q61R) in 3 of 5 IUPs, described for the first time in this neoplasm.
|
25097040 |
2014 |
|
Familial medullary thyroid carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Of the seven RET wild-type MTCs, four cases (57.1 %) harbored a RAS mutation: three in HRAS (all Q61R) and one in KRAS (G12R).
|
24828033 |
2014 |
|
Papilloma
|
|
0.010 |
GeneticVariation
|
BEFREE |
DMBA/TPA treatment of Hras(G12V) knock-in mice induced an even greater incidence of papillomas, which either harbored Hras(G12V) amplification or developed an Hras(Q61L) mutation in the second allele.
|
24240680 |
2014 |